The optimal management and prognosis of locally recurrent nonesmall-cell lung cancer after surgery is not well described. To our knowledge, this is the largest reported series of such patients treated with definitive radiation. We found generally favorable survival using this approach (median, 23 months), and patients treated with higher radiation doses and intensity-modulated radiation did particularly well. Introduction: Locoregional recurrence after resection of nonesmall-cell lung cancer (NSCLC) is common. We examined outcomes after definitive radiotherapy (RT) to identify prognostic factors for survival and further recurrence. Patients and Methods: We reviewed 152 patients who received RT for locoregional recurrent (LR)-NSCLC, and analyzed subsequent overall survival (OS), locoregional failure (LRF), distant metastasis (DM), and any disease progression (LRF and DM). Results: Two-and 5-year OS were 49% and 28%, respectively. Two-and 5-year LRF, DM, and any disease progression rates were 40% and 45%, 33% and 37%, and 53% and 57%, respectively. Performance status and intensity-modulated RT (IMRT) were independently associated with OS, as was RT dose 60 Gy. Stage, chemotherapy at recurrence, and surgery to recurrence interval were not independently associated with outcome. Chemotherapy at initial presentation, adenocarcinoma histology, and male sex were independently associated with higher rates of DM. Conclusion: To our knowledge, this is the largest reported series of LR-NSCLC treated with definitive RT. Survival appears comparable to or greater than that of primary NSCLC. Subsequent LRF is more common than distant failure. Established prognostic factors for primary NSCLC, such as chemotherapy and stage, were not clearly prognostic in this analysis. IMRT and higher RT doses were associated with improved survival, though IMRT patients were also treated more recently. These data support definitive-intent RT with optimal dose and technique in such patients.
Introduction
Surgery is typically the treatment of choice for resectable nonesmall-cell lung cancer (NSCLC). Although distant metastasis is the primary determinant of subsequent survival, isolated intrathoracic recurrence is a common pattern of failure after surgery, with reported rates ranging from 5% to 38%. 1, 2 In the absence of distant metastases, a second attempt at curative local therapy is often warranted. However, many such patients are no longer fit to undergo further surgery because of diminished pulmonary reserve, technical unresectability of recurrent disease, or both. Definitive radiotherapy (RT) is then the local treatment modality of choice. Although locally recurrent NSCLC after surgery is common, there are few data to guide treatment for these patients or predict their outcome. In the absence of conclusive data, many clinicians prescribe RT in the same way as primary NSCLC of comparable disease extent. Small series suggest that definitive RT can achieve These data were presented, in preliminary and abstract form, at the ASTRO Annual Meeting in Boston, Massachusetts in October 2012. 1 outcomes similar to those of primary NSCLC, but this has not been evaluated in a large cohort of patients. 1, [3] [4] [5] [6] In addition, it is unclear whether the same prognostic factors and treatment approaches that have been proven valid in primary NSCLC, such as the use of sequential or concurrent chemotherapy with RT, are also applicable in the locally recurrent setting. We therefore sought to review a large cohort of patients who were treated with definitive RT for localized recurrence of NSCLC after surgical resection. In addition to characterizing the outcomes of this group as whole, we also evaluated whether patient and disease factors at initial presentation and at recurrence were predictive of disease control. In particular, we examined whether extent of disease at initial presentation and recurrence, interval between surgery and recurrence, use of chemotherapy, and choice of RT dose and technique had an effect on outcome.
Patients and Methods

Patient Selection
Institutional review and privacy boards approved this study, and patient confidentiality was maintained as required by the Health Insurance Portability and Accountability Act. Institutional databases were queried to identify patients who received curative-intent ("salvage") RT for locoregionally recurrent NSCLC between 1994 and 2012 at our institution. All patients had to have received curative-intent surgery that was at least macroscopically complete, and then developed recurrent NSCLC within 5 years of surgery. Disease was only considered recurrent if it was limited to the ipsilateral lung, ipsilateral thoracic nodes, and/or bilateral mediastinal and supraclavicular nodes, and was of the same histology as the initial tumor. In cases in which histologic confirmation of recurrent tumor was not obtained, we only included cases if the treating physician considered the patient to have locally recurrent disease on the basis of the clinical scenario.
Treatment
Patients who received radiation with palliative intent (< 40 Gy in conventional fractionation) were excluded. Patients were immobilized in a customized foam cradle with arms above their heads, and radiation dose was prescribed to the isodose line encompassing the planning tumor volume (PTV). Treatment fields for conventionally fractionated RT were generally limited to the recurrent tumor, involved nodes, and the ipsilateral hilum. Typical margins for conventional RT were 1.2 to 1.5 cm from gross tumor volume (GTV) to PTV, or 2 cm to block edge.
Patients treated with stereotactic body RT (SBRT) received 6 Gy per fraction (median of 4 fractions), with on-board computed tomography (CT) guidance at each fraction. Patients were offered SBRT according to the judgement of the treating physician, using criteria analogous for those used to select SBRT for primary lung cancer at our institution. In general, SBRT was considered for patients with node-negative tumors measuring 5 cm. Fourdimensional CT simulation was used to define the respiratory excursion of the GTV, and the PTV consisted of an additional 7-to 8-mm expansion. Dose was then prescribed to the 100% isodose line encompassing the PTV using intensity-modulated beams.
Data Collection
All patient charts were retrospectively reviewed to obtain patient, disease, and treatment factors at the time of initial presentation of NSCLC, as well as recurrence. Patient factors included age, sex, weight loss, and performance status. Disease factors included American Joint Committee on Cancer (AJCC) stage (on the basis of the seventh edition criteria), histology, margin status after surgery (R0 vs. R1), interval between resection and recurrence, and maximum standardized uptake value in patients who underwent positron emission tomography imaging at the time of recurrence. All patients were assigned a recurrent "stage," using the same AJCC staging criteria as used for primary NSCLC. We also distinguished patients whose disease recurred in lymph nodes only from those who had recurrences involving lung parenchyma. Treatment factors included use of chemotherapy at time of surgery, chemotherapy at time of salvage RT (either sequential or concurrent), RT technique (noneintensity-modulated RT [IMRT] vs. IMRT vs. SBRT), and RT dose ( 60 Gy or < 60 Gy, in the subset of patients not receiving SBRT). Subsequent locoregional failure (LRF; after salvage RT) was defined as clinical evidence of disease progression within the ipsilateral hemithorax.
Statistical Analysis
Overall survival was estimated using KaplaneMeier methods. The cumulative incidence of LRF, distant metastasis, and any progression were estimated, and death without disease progression was treated as a competing event. All follow-up was calculated from the date of RT completion. Cox regression analysis was performed to examine clinical and treatment factors related to overall survival, whereas competing risk regression was used to analyze association with time to LRF, distant metastasis, and any progression. Overall P values were derived from likelihood ratio tests comparing a model including the variable with a null model.
Multivariable analysis was performed in which all variables with P < .1 in univariate analysis were included into a model for each end point (the cutoff was P < .05 for the end point of distant metastasis, because of many associated variables and the small number of events). Additional variables of significant clinical interest were also examined in the multivariable model. Specifically, recurrent stage was added to the model for overall survival, and surgery to recurrence interval was added to the model for distant metastasis. Overall P values were derived from likelihood ratio tests comparing a model with and without the variable. Because radiation doses for patients treated with SBRT are not comparable with doses with non-SBRT techniques, a separate multivariable model was fitted on the subset of non-SBRT patients to examine the importance of RT dose on overall survival.
Results
Patient Characteristics
We identified 152 patients who satisfied the study criteria and were included in the present study. Patients underwent RT between the years 1994 and 2012. The median age at time of salvage RT was 70 years (range, 48-89 years). Median interval between surgery and diagnosis of locoregional recurrence was 17 months (range, 2-60 months). For non-SBRT patients, the median RT dose was 66 Gy
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Radiotherapy for Locally Recurrent NSCLC (range, 45-90 Gy) and all patients were treated with conventional fractionation (1.8-2.0 Gy per fraction). The median SBRT dose was 45 Gy (range, 30-60 Gy). Patient characteristics are listed in Table 1 . The median follow-up for the cohort was 23 months (25 months among surviving patients).
Overall Survival
Median survival for the entire cohort was 23 months (95% confidence interval [CI], 18-34 months), and the 2-and 5-year estimate of OS was 49% (95% CI, 40%-57%) and 28% (95% CI, 20%-37%), respectively ( Figure 1 ). In univariate analysis, the following factors were associated with improved OS (P < .1): lower stage at initial presentation, Karnofsky performance status (KPS) 80% and use of IMRT. Improved survival was also observed for RT dose 60 Gy in the non-SBRT subset (P ¼ .02). Recurrent stage was marginally associated with survival (P ¼ .13) and was also chosen for multivariable modeling.
In a multivariable model, higher KPS (hazard ratio [HR], 0.63; 95% CI, 0.39-0.99; P ¼ .05) remained independently associated with improved survival and initial stage II versus stage I was borderline significant (P ¼ .06; Table 2 ). In a separate multivariable model excluding the SBRT patients, RT dose 60 Gy remained significantly associated with improved survival (HR, 0.5; 95% CI, 0.28-0.88; P ¼ .02), as did use of IMRT (HR, 0.61; 95% CI, 0.39-0.94; P ¼ .03).
Locoregional Failure
Sixty-four patients (42%) experienced subsequent LRF. The 2-and 5-year estimate of LRF was 40% (95% CI, 32%-48%) and 45% (95% CI, 37%-54%), respectively ( Figure 2) . In univariate analysis, higher recurrent stage and use of chemotherapy at the time of initial surgery were significantly associated with increased LRF (P < .05). Higher initial stage and shorter interval between surgery and recurrence were borderline significant (P < .1) and also included in the multivariable analysis. However, none of the candidate factors was independently associated with LRF, including RT dose in the non-SBRT patients. IMRT and SBRT were associated with a numerically lower risk of LRF (HR, 0.81 and 0.56, respectively), but the association of RT technique with LRF was not statistically significant (P ¼ .38).
Distant Metastasis
Fifty-three patients (35%) experienced distant metastasis. The 2-and 5-year estimate of distant metastasis was 33% (95% CI, 25%-40%) and 37% (95% CI, 28%-46%), respectively ( Figure 3 ). 
Any Progression
The 2-and 5-year rate of any progression (locoregional or distant) was 53% (95% CI, 44%-61%) and 57% (95% CI, 49%-64%), respectively ( Figure 4) . In univariate analysis, shorter surgery to recurrence interval, use of chemotherapy with surgery, and younger age correlated with increased risk of progression (P .05). Initial stage (P ¼ .08) and recurrent stage (P ¼ .11) were also included in the multivariable analysis. None of the factors were independently associated with progression.
Discussion
To our knowledge, this is the largest series yet reported of locoregionally recurrent NSCLC after surgical resection treated with definitive RT. A large cohort of postresection recurrent NSCLC was recently described by investigators in Taiwan, but a relatively small proportion received RT. 7 Our purpose was to describe the outcomes of patients deemed eligible for definitive treatment with RT. We found overall survival broadly comparable with that of primary locally-advanced NSCLC, with median survival of 23 months and 5-year survival of 28%. This compares favorably with reported median survival rates ranging from 15 to 27 months in primary stage III NSCLC patients treated with chemotherapy and radiation. 8, 9 We hypothesized that tumor stage, particularly stage at the time of recurrence, would correlate with outcome. Although patients with recurrent stage II and III disease had worse survival than recurrent stage I, recurrent stage was not a significant prognostic factor in univariate or multivariable analysis. Previously published series have also indicated that median survival in these patients is comparable with or better than primary NSCLC. In an early report from Fox Chase Cancer Center in which 37 recurrent patients were compared with 759 primary NSCLC patients no significant difference in survival was reported. 5 In a more study from the University of Michigan, 54 recurrent patients were compared with 607 primary NSCLC patients and a median survival of 20 months in the recurrent patients was reported, which was significantly better than that of the primary NSCLC patients. 4 Other groups have evaluated the effect of combining chemotherapy with RT in this setting. A small Canadian series focused exclusively on patients treated with concurrent chemoradiation and reported a relatively favorable median survival of 27 months. 10 The most recent and heretofore largest series treated with definitive RT, from Korea, suggested that concurrent chemoradiation led to significantly better outcomes compared with RT alone. 11 However, we did not see any clear benefit of chemotherapy on outcomes in our larger cohort, which might be related in part to the observation that LRF was a higher risk for these patients than distant metastasis. Although we did not identify a clear correlation of chemotherapy with outcomes, we did for radiation technique and dose. For patients with primary NSCLC, the optimal RT dose is considered to be 60 Gy. 12 RT dose 60 Gy also was independently associated with improved OS among patients who received conventionally fractionated RT in our cohort, even after adjusting for other factors likely to affect prescribed dose, such as recurrent stage (because bulkier disease is less likely to be amenable to highdose RT). However, RT dose 60 Gy was not significantly associated with the risk of local recurrence or distant metastasis, which raises the question of how higher radiation dose contributes to increased survival. We also found that IMRT was associated with improved survival compared with conventional radiation techniques. Although the benefit of IMRT has not been conclusively established in NSCLC, this association has also been observed in primary NSCLC, and might be because of the lower toxicity that can be achieved with this technique. 13 Reducing RT-related toxicity might be especially relevant for these patients, who have reduced lung capacity and other postsurgical changes from previous resection. However, we cannot rule out the possibility that the observed benefit of higher doses and IMRT is because of other confounding factors not accounted for in our multivariable analysis. In particular, IMRT was much more likely to be used in the more recently treated patients (10% of patients treated before 2006, compared with 69% of patients treated after 2006), and therefore the IMRT patients might have benefitted from other advances in treatment over this time. It must be acknowledged that the long time frame of this study, and the significant heterogeneity in the patient population, makes it 
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Clinical Lung Cancer May 2017 -e165 inherently difficult to isolate the effect of radiation technique and dose on outcome, and these associations must be considered only hypothesis-generating. To our knowledge, this is also the first series of locoregionally recurrent NSCLC to include patients treated with SBRT, which has shown great promise in primary NSCLC and therefore is an attractive option for patients whose local recurrences are technically amenable to this technique.
14 Use of SBRT was not an independent prognostic factor for outcome in our series, but the limited number of SBRT patients limits our ability to draw firm conclusions about the comparative effectiveness of SBRT in this setting. Overall, however, these data support the use of high-dose RT and modern radiation techniques for locally recurrent NSCLC, as is the case for primary NSCLC.
Our study confirmed that a number of factors known to affect outcome for primary NSCLC are also applicable in the postresection recurrent setting. In particular, poor performance status is an adverse prognostic factor, and adenocarcinoma histology is associated with a higher risk of distant metastasis. Some previous series suggested that longer interval between surgery and recurrence was favorable. 6, 11 In univariate analysis, we observed correlation with local failure and with any progression, but no significant association was seen after multivariable analysis. A major strength of our analysis is the large number of patients, which provided the opportunity to assess the effect of multiple clinical and treatment factors on disease control and survival outcomes. Only a handful of studies of postresection recurrent NSCLC have analyzed multiple prognostic factors and disease control end points in addition to survival, and none have analyzed the effect of IMRT or SBRT. 11, 15 Our data support an aggressive approach to definitive RT, using high-dose IMRT or SBRT. However, these data do not provide clear evidence for integrating chemotherapy into the salvage treatment, which is otherwise a well established strategy for improving outcomes in primary NSCLC. Another distinguishing feature of this series is our analysis of patterns of failure. Most published series have only reported survival. We recorded whether patients experienced disease progression in locoregional or distant sites after definitive RT, and found that LRF is a somewhat more likely event than distant metastasis. This observation might reflect the underlying biology of locally recurrent NSCLC: because these tumors did not widely metastasize after surgery, they might not be as prone to distant metastasis after salvage RT. This suggests that attempts to optimize local control, such as through RT technique and dose, might be particularly beneficial for this population.
The major limitation of this study is its retrospective nature, and the heterogeneity of the patients included with respect to stage and treatment of initial as well as recurrent disease. Although we made efforts to adjust for clinical and treatment factors that might confound the analysis of prognostic factors, it is impossible to account for every potential factor, especially when the individual patient scenarios and treatments are so diverse. However, no prospective data exist for this subset of NSCLC patients, nor are any likely to be produced in the near future.
Conclusion
This large cohort and detailed analysis of prognostic factors and disease outcomes might be of interest and help to clinicians facing the scenario of locoregionally recurrent NSCLC after surgical resection. We conclude that favorable outcomes can be achieved with definitive RT, and that the use of IMRT and higher RT doses is encouraged.
Clinical Practice Points
Localized recurrence of NSCLC after surgery is relatively common. RT can be used in this situation with curative intent, but relatively little is known about outcomes or prognostic factors using this approach. Most published series have not analyzed the effect of factors such as interval between surgery and recurrence, use of chemotherapy, and dose and type of RT, because patient numbers are small. This is the largest known series of such patients (n ¼ 152), and we undertook a detailed analysis of potential prognostic factors and analyzed local and distant failure rates, as well as survival. We found a relatively favorable 5-year survival rate of 28%. Interval between surgery and recurrence, and use of chemotherapy were not clearly prognostic, but higher radiation doses and the use of IMRT were independently associated with improved outcomes. These data support the use of curative-intent RT for locally recurrent NSCLC, using optimal doses and techniques. 
